TribLIVE

| USWorld

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

FDA probes new pancreas risks linked with diabetes drugs

Email Newsletters

Click here to sign up for one of our email newsletters.

Daily Photo Galleries

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

By The Associated Press
Sunday, March 17, 2013, 6:03 p.m.
 

WASHINGTON — The Food and Drug Administration is looking into new evidence that a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.

The agency said samples of pancreas tissue taken from a small number of patients showed inflammation and cellular changes that often precede cancer. Academic researchers took the samples from diabetes patients who were taking the new medications, after they died from various causes.

Details of the research have not yet been published, but the agency said in an online statement it is seeking more information.

While the FDA has issued previous alerts about the pancreatitis risk, the agency had not notified the public about precancerous cell changes seen with the drugs.

For now, regulators say they are still investigating the issue.

“FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer,” the agency said in an online statement. “At this time, patients should continue to take their medicine as directed until they talk to their health care professional.”

The drugs under review come from a wave of recently approved diabetes medications, including Merck's Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon, among others. All the drugs mimic natural hormones that the body usually produces to spur insulin production after a meal.

People with type 2 diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Many diabetics require multiple drugs with different mechanisms of action to control their blood sugar levels.

With more than 25 million people living with diabetes in the United States, some of the world's biggest drugmakers have introduced new treatments in recent years, though safety questions have emerged.

The FDA previously added information about cases of pancreatitis, some of them fatal, to the labels of Byetta in 2007, Januvia and Janumet in 2009.

A recent study of insurance records found that use of those drugs could double the risk of developing acute pancreatitis, according to the FDA.

Januvia is a once-a-day pill. Janumet combines the drug with metformin, a decades-old drug commonly prescribed for diabetes. Byetta is a twice-a-day injection originally developed by Amylin Pharmaceuticals. Bristol-Myers acquired the drug last year, along with the newer formulation Bydureon, which is taken once-a-week.

Byetta and Bydureon are part of a drug class that mimics the GLP-1 hormone, triggering insulin production after a meal. Januvia and Janumet work by blocking the DPP-4 enzyme, which spurs release of more insulin from the pancreas.

The pancreas produces various hormones, including insulin, that help the body break down sugar. Pancreatitis causes an inflammation of the organ and can lead to fatal complications, including difficulty breathing and kidney failure.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Nation

  1. Pressure mounts for Biden to join 2016 White House race
  2. 2 women advance to final phase of Army Ranger training
  3. Marines finally ready to roll out controversial fighter jet
  4. Body of Forest Service firefighter recovered amid Northern California blaze
  5. State Department accuses top Clinton aide of violations
  6. 4 dead, 65 sickened in Bronx by Legionella
  7. U.S., Hong Kong researchers develop computer model to examine spread of influenza
  8. Obama’s nuclear deal lobbying sways Democrats
  9. Florida panther population cut by 10 percent in 7 months
  10. Name of cop withheld in shooting of motorist in South Carolina
  11. Food industry players fighting proposed dietary guidelines drop millions on lobbyists